Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TTN003
MIFTS: 64

Tetanus

Categories: Infectious diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Tetanus

About this section

MalaCards integrated aliases for Tetanus:

Name: Tetanus 11 19 58 75 53 41 43 14 16 71 33
Lockjaw 19 2
Infection Due to Clostridium Tetani 11
Clostridial Tetanus 11
Lock-Jaw 33

Characteristics:


Prevelance:

<1/1000000 (France, Europe, Malta, Slovakia, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Greece, Hungary, Ireland, Italy, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, United Kingdom) 1-9/1000000 (Slovenia) 58

Age Of Onset:

All ages 58

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 31 32
ICD11: 33
Orphanet: 58  
Rare neurological diseases
Rare infectious diseases


External Ids:

Disease Ontology 11 DOID:11338
ICD9CM 34 037
MeSH 43 D013742
NCIt 49 C85185
SNOMED-CT 68 154312006
ICD10 31 A35
MESH via Orphanet 44 D013742
ICD10 via Orphanet 32 A33 A34 A35
UMLS via Orphanet 72 C0039614
Orphanet 58 ORPHA3299
ICD11 33 1793762788
UMLS 71 C0039614
Sources

Summaries for Tetanus

About this section

MedlinePlus: 41 Tetanus is a serious illness caused by Clostridium bacteria. The bacteria live in soil, saliva, dust, and manure. The bacteria can enter the body through a deep cut, like those you might get from stepping on a nail, or through a burn. The infection causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw. This makes it impossible to open your mouth or swallow. Tetanus is a medical emergency. You need to get treatment in a hospital. A vaccine can prevent tetanus. It is given as a part of routine childhood vaccination. Adults should get a tetanus shot, or booster, every 10 years. If you get a bad cut or burn, see your doctor - you may need a booster. Immediate and proper wound care can prevent tetanus infection.

MalaCards based summary: Tetanus, also known as lockjaw, is related to diphtheria and poliomyelitis, and has symptoms including fever and pruritus. An important gene associated with Tetanus is VAMP2 (Vesicle Associated Membrane Protein 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Benzocaine and Tannic acid have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, skeletal muscle and skin, and related phenotypes are dysphagia and muscle stiffness

CDC: 2 Tetanus is different from other vaccine-preventable diseases because it does not spread from person to person. The bacteria are usually found in soil, dust, and manure and enter the body through breaks in the skin - usually cuts or puncture wounds caused by contaminated objects. Today, tetanus is uncommon in the United States, with an average of about 30 reported cases each year. Nearly all cases of tetanus are among people who did not get all the recommended tetanus vaccinations. This includes people who have never received a tetanus vaccine and adults who don't stay up to date on their 10-year booster shots.

Disease Ontology: 11 A primary bacterial infectious disease that results in prolonged contraction of skeletal muscle fibers, has material basis in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli.

GARD: 19 A toxin-mediated infection due to the anaerobic bacteria Clostridium tetani and characterized by spasms and contractions of the skeletal muscles, the disease is often lethal.

Orphanet: 58 A toxin-mediated infection due to the anaerobic bacteria Clostridium tetani and characterized by spasms and contractions of the skeletal muscles, the disease is often lethal.

Wikipedia: 75 Tetanus, also known as lockjaw, is a bacterial infection caused by Clostridium tetani, and is... more...
Sources

Related Diseases for Tetanus

About this section

Diseases related to Tetanus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 908)
# Related Disease Score Top Affiliating Genes
1 diphtheria 32.6 IL5 IL4 IL2RA IL2 IL13 IFNG
2 poliomyelitis 32.0 IL2 IL10 IFNG
3 mumps 31.4 IL2 IL10 IFNG CD40LG
4 foodborne botulism 31.3 VAMP2 SNAP25 SNAP23 NSF
5 cholera 31.2 IL5 IL4 IL10 IFNG CD79A
6 respiratory failure 31.2 IL5 IL4 IL2 IL13 IL10 IFNG
7 rubella 31.2 IL5 IL4 IL2RA IL2 IL10 IFNG
8 smallpox 31.1 IL4 IL2 IFNG
9 allergic disease 31.0 IL5 IL4 IL2 IL13 IL10 IFNG
10 hepatitis a 31.0 IL4 IL10 IFNG
11 graft-versus-host disease 30.9 IL2 IL10 IFNG
12 neuritis 30.9 IL4 IL10 IFNG
13 chickenpox 30.9 IL4 IL2 IL10 IFNG CD27
14 leprosy 3 30.8 IL5 IL4 IL2 IL13 IL10 IFNG
15 herpes zoster 30.7 IL2 IL10 IFNG
16 purpura 30.7 IL4 IL2 IL10 IFNG CD79A
17 otitis media 30.7 IL5 IL4 IL2 IL13 IL10 IFNG
18 exanthem 30.7 IL4 IL2 IL10 IFNG
19 meningitis 30.6 IL5 IL4 IL2 IL13 IL10 IFNG
20 onchocerciasis 30.6 IL5 IL4 IL2 IL13
21 myocarditis 30.6 IL4 IL2 IL10 IFNG CD40LG
22 urticaria 30.6 IL5 IL4 IL13 IL10 IFNG
23 lepromatous leprosy 30.6 LTA IL4 IL2 IL10 IFNG
24 human immunodeficiency virus type 1 30.6 IL2 IL10 IFNG CCR7
25 yellow fever 30.6 LTA IL5 IL4
26 pneumonia 30.5 IL5 IL4 IL13 IL10 IFNG CD40LG
27 schistosomiasis 30.5 IL5 IL4 IL2 IL13 IL10 IFNG
28 ige responsiveness, atopic 30.5 IL5 IL4 IL13 IL10 IFNG
29 dermatitis 30.5 IL5 IL4 IL2 IL13 IL10 IFNG
30 erythema multiforme 30.5 IL5 IL4 IL2 IL13 IFNG
31 elephantiasis 30.5 IL5 IL4 IL13 IL10
32 myasthenia gravis 30.5 LTA IL4 IL2 IL10 IFNG
33 thrombocytopenia 30.5 IL4 IL2 IL10 IFNG CD79A CD40LG
34 demyelinating disease 30.5 IL4 IL2 IL10 IFNG
35 parasitic helminthiasis infectious disease 30.5 IL5 IL4 IL2 IL13 IL10 IFNG
36 filarial elephantiasis 30.5 IL5 IL4 IL2 IL13 IL10
37 plague 30.4 IL4 IL2 IL10
38 respiratory syncytial virus infectious disease 30.4 IL5 IL13
39 spondyloarthropathy 1 30.4 IL10 CD79A CD40LG
40 sjogren syndrome 30.4 IL2RA IL10 CD79A CD40LG
41 gastroenteritis 30.4 IL5 IL4 IL10 IFNG
42 viral infectious disease 30.4 IL4 IL2RA IL2 IL13 IL10 IFNG
43 osteomyelitis 30.4 IL4 IL10 IFNG
44 wound botulism 30.4 VAMP2 SNAP25
45 common cold 30.4 IL5 IL4 IL2 IL13 IL10 CD40LG
46 glomerulonephritis 30.4 IL4 IL10 CD79A CD40LG
47 toxic shock syndrome 30.4 LTA IL4 IL2 IL10 IFNG
48 acquired immunodeficiency syndrome 30.3 IL2RA IL2 IL10 IFNG CD79A CD40LG
49 severe combined immunodeficiency 30.3 IL5 IL4 IL2RA IL2 IL13 IL10
50 immunoglobulin g deficiency 30.3 CD79A CD40LG

Graphical network of the top 20 diseases related to Tetanus:



Diseases related to Tetanus
Sources

Symptoms & Phenotypes for Tetanus

About this section

Human phenotypes related to Tetanus:

58 30 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0002015
2 muscle stiffness 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0003552
3 trismus 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0000211
4 opisthotonus 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0002179
5 risus sardonicus 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0040212
6 fever 58 30 Frequent (33%) Frequent (79-30%)
 HP:0001945
7 rigidity 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002063
8 tachycardia 58 30 Frequent (33%) Frequent (79-30%)
 HP:0001649
9 intermittent painful muscle spasms 58 30 Frequent (33%) Frequent (79-30%)
 HP:0011964
10 localized skin lesion 58 30 Frequent (33%) Frequent (79-30%)
 HP:0011355
11 stiff neck 58 30 Frequent (33%) Frequent (79-30%)
 HP:0025258
12 humoral immunodeficiency 58 30 Frequent (33%) Frequent (79-30%)
 HP:0005363
13 tremor 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001337
14 hypertension 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000822
15 bowel incontinence 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002607
16 cranial nerve paralysis 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0006824
17 elevated circulating creatine kinase concentration 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0003236
18 abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002027
19 tachypnea 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002789
20 coma 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001259
21 respiratory distress 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002098
22 bradycardia 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001662
23 rigors 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0025145
24 autonomic bladder dysfunction 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0005341
25 laryngospasm 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0025425
26 elevated urinary norepinephrine 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0003345
27 elevated urinary epinephrine 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0003639
28 spasticity of pharyngeal muscles 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0002501
29 hypertonia 58 Frequent (79-30%)
30 abnormal autonomic nervous system physiology 58 Occasional (29-5%)

UMLS symptoms related to Tetanus:


fever; pruritus

GenomeRNAi Phenotypes related to Tetanus according to GeneCards Suite gene sharing:

25 (show all 49)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.53 IL10 CCR7
2 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.53 IL2RA
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.53 IL13
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.53 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.53 IL2RA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.53 CCR7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.53 IL2RA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.53 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.53 VAMP7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.53 IL2RA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.53 VAMP7
12 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.53 IL2RA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.53 NSF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.53 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.53 VAMP7
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.53 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-165 10.53 IL13
18 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.53 CCR7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.53 IL2RA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-179 10.53 NSF VAMP7
21 Increased shRNA abundance (Z-score > 2) GR00366-A-181 10.53 IL13
22 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.53 VAMP7
23 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.53 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.53 IL13
25 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.53 IL2RA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.53 NSF
27 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.53 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.53 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.53 CCR7
30 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.53 IL2RA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.53 NSF
32 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.53 IL2RA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.53 VAMP7
34 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.53 IL2RA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.53 VAMP7
36 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.53 NSF
37 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.53 IL10 IL2RA
38 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.53 IL10
39 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.53 IL13
40 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.53 VAMP7
41 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.53 IL10
42 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.53 IL10 IL2RA
43 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.53 IL10
44 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.53 VAMP7
45 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.53 IL10
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.53 IL10
47 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.53 NSF
48 no effect GR00402-S-1 10.18 CCR7 CD27 CD40LG CD79A IFNG IL13
49 no effect GR00402-S-2 10.18 CCR7 CD27 CD40LG CD79A IFNG IL10

MGI Mouse Phenotypes related to Tetanus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CCR7 CD40LG CD79A IFNG IL10 IL13
2 nervous system MP:0003631 10.23 CCR7 CD40LG CD79A IFNG IL10 IL13
3 no phenotypic analysis MP:0003012 10.13 CCR7 CD79A IFNG IL10 IL13 IL2
4 endocrine/exocrine gland MP:0005379 10.11 CCR7 CD40LG IFNG IL10 IL13 IL2
5 immune system MP:0005387 10.1 CCR7 CD27 CD40LG CD79A IFNG IL10
6 liver/biliary system MP:0005370 10.03 CD79A IFNG IL10 IL2 IL4 IL5
7 digestive/alimentary MP:0005381 9.92 CCR7 IFNG IL10 IL13 IL2 IL2RA
8 hematopoietic system MP:0005397 9.83 CCR7 CD27 CD40LG CD79A IFNG IL10
9 respiratory system MP:0005388 9.81 IFNG IL10 IL13 IL2 IL2RA IL4
10 mortality/aging MP:0010768 9.5 CD40LG CD79A IFNG IL10 IL13 IL2
Sources

Drugs & Therapeutics for Tetanus

About this section

Drugs for Tetanus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
2
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
3
Aluminium phosphate Approved, Investigational Phase 4 7784-30-7
4
Remifentanil Approved Phase 4 132875-61-7 60815
5
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
6
Iron Approved Phase 4 7439-89-6 29936
7
Pentetic acid Approved Phase 4 67-43-6
8 Vaccines Phase 4
9 Immunologic Factors Phase 4
10 Anti-Ulcer Agents Phase 4
11 Adjuvants, Immunologic Phase 4
12 Antacids Phase 4
13 Gastrointestinal Agents Phase 4
14 Antitoxins Phase 4
15 Analgesics Phase 4
16 Antidotes Phase 4
17 Calcium, Dietary Phase 4
18 Protective Agents Phase 4
19 Analgesics, Opioid Phase 4
20 Narcotics Phase 4
21 Fibrinolytic Agents Phase 4
22 Anticoagulants Phase 4
23 Iron Chelating Agents Phase 4
24 Chelating Agents Phase 4
25 Immunoglobulins, Intravenous Phase 4
26 Immunoglobulins Phase 4
27 Antibodies Phase 4
28 gamma-Globulins Phase 4
29 Rho(D) Immune Globulin Phase 4
30
Calcium Nutraceutical Phase 4 7440-70-2 271
31
Lactitol Approved, Investigational Phase 3 585-86-4 157355
32
Deferiprone Approved Phase 3 30652-11-0 2972
33 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
34 Cathartics Phase 3
35 Laxatives Phase 3
36 Immunosuppressive Agents Phase 3
37 polysaccharide-K Phase 3
38
Fingolimod Hydrochloride Phase 3 162359-56-0
39 Somatomedin B Phase 3
40 Hemagglutinins Phase 3
41 Taxane Phase 3 108169
42 PENTA Phase 3
43
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
44
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
45
Fluorouracil Approved Phase 2 51-21-8 3385
46
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
47
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 2 14769-73-4 26879
48
Aluminum sulfate Approved Phase 2 10043-01-3
49
Basiliximab Approved, Investigational Phase 2 179045-86-4
50
Sargramostim Approved, Investigational Phase 2 123774-72-1

Interventional clinical trials:

(show top 50) (show all 298)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR) Unknown status NCT04638985 Phase 4
2 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA) Unknown status NCT04636827 Phase 4
3 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
4 A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine} Unknown status NCT04056728 Phase 4
5 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
6 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
7 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
8 Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age Completed NCT00601835 Phase 4
9 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. Completed NCT00548171 Phase 4
10 An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. Completed NCT00325156 Phase 4
11 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexaâ„¢) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
12 Antibody Persistence in Children Previously Vaccinated With Three Doses of Infanrix Hexaâ„¢ or Infanrix-IPV/Hibâ„¢ Completed NCT01358825 Phase 4
13 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexaâ„¢ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
14 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
15 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
16 A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot Completed NCT02783170 Phase 4
17 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
18 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACELâ„¢ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
19 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
20 Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life. Completed NCT00392808 Phase 4
21 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4
22 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
23 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
24 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
25 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACELâ„¢ and BOOSTRIX® Completed NCT00319553 Phase 4
26 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
27 Diphteria-tetanus-pertussis (DTP) Vaccination and Child Survival: Randomized Study of Not Providing DTP Vaccination Together With or After Measles Vaccination Completed NCT00244673 Phase 4
28 Regulatory Post-Marketing Surveillance (PMS) Study for ADACELâ„¢ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
29 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIMâ„¢(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
30 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
31 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
32 Interest of the Gradient of Nociceptive Indexes After a Tetanus (100 Hz, 60 Milliamperes, 30 Seconds) at a Fixed Remifentanil Effect Site Concentration to Adjust Remifentanil Before Tracheal Intubation and Skin Incision Completed NCT02884310 Phase 4 Remifentanil adapted to SPI;Remifentanil fixed
33 Adacel® (TdaP-Tetanus, Diphtheria, Acellular Pertussis) Booster Vaccination of Acellular Pertussis Vaccine-primed Individuals for Cell Mediated Immunity Assay Development Completed NCT04543669 Phase 4
34 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
35 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
36 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
37 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
38 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
39 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIMâ„¢) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIMâ„¢ in the Study E2I34 Completed NCT01031303 Phase 4
40 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactraâ„¢) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
41 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
42 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
43 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
44 Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
45 Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child Completed NCT01711645 Phase 4
46 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4
47 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants Completed NCT00753649 Phase 4
48 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
49 Immunogenicity and Reactogenicity Study of a New Formulation of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
50 Evaluation of GSK Biologicals' Boostrixâ„¢ in Healthy Adults, 10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4

Search NIH Clinical Center for Tetanus

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chlorpromazine
Chlorpromazine hydrochloride
cyclobenzaprine
Cyclobenzaprine hydrochloride
Methocarbamol
Metocurine iodide
Orphenadrine
Orphenadrine Citrate
Orphenadrine Hydrochloride
Tetanus Antitoxin
TETANUS ANTITOXIN,EQUINE
Tetanus immune globulin
Tetanus immune globulin, human
tetanus toxoid vaccine, inactivated

Cochrane evidence based reviews: tetanus

Sources

Genetic Tests for Tetanus

About this section
Sources

Anatomical Context for Tetanus

About this section

Organs/tissues related to Tetanus:

MalaCards : Spinal Cord, Skeletal Muscle, Skin, Brain, Heart, T Cells, Bone Marrow
Sources

Publications for Tetanus

About this section

Articles related to Tetanus:

(show top 50) (show all 24604)
# Title Authors PMID Year
1
From Bacterial Poisons to Toxins: The Early Works of Pasteurians. 62 41
36356009 2022
2
Tetanus immunization among healthcare professionals: cross-sectional study in Turkey. 62 41
36332212 2022
3
Resource mobilization for tetanus vaccination in Vietnam: Uptake, demand and willingness to pay among women of reproductive age. 62 41
36330125 2022
4
In vitro cytokine responses to periodontal pathogens: generalized aggressive periodontitis is associated with increased IL-6 response to Porphyromonas gingivalis. 53 62
20500696 2010
5
Failure of highly active antiretroviral therapy in reconstituting immune response to Clostridium tetani vaccine in aged AIDS patients. 53 62
20224419 2010
6
Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients. 53 62
19744828 2010
7
[Conditional cell targeting and reversible synapse silencing to study neural circuits]. 53 62
20297730 2010
8
CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function. 53 62
20194631 2010
9
Stimulation of anti-polio and anti-HSV IgA pre-plasma cell response in blood following parenteral immunization with tetanus-diphtheria vaccine. 53 62
20003921 2010
10
Transport of AMPA receptors during long-term potentiation is impaired in rats with hepatic encephalopathy. 53 62
19450629 2009
11
VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. 53 62
19910495 2009
12
Subcellular localization of the carbohydrate Lewis(x) adhesion structure in hippocampus cell cultures. 53 62
19576189 2009
13
T-cell reactivity during tapering of immunosuppression to low-dose monotherapy prednisolone in HLA-identical living-related renal transplant recipients. 53 62
19300195 2009
14
The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope. 53 62
19010547 2009
15
Role of HRB in clathrin-dependent endocytosis. 53 62
18819912 2008
16
Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. 53 62
18753334 2008
17
Transient silencing of synaptic transmitter release from specific neuronal types by recombinant tetanus toxin light chain fused to antibody variable region. 53 62
18775748 2008
18
The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. 53 62
18653385 2008
19
GLUT4 vesicle recruitment and fusion are differentially regulated by Rac, AS160, and Rab8A in muscle cells. 53 62
18650435 2008
20
Effect of HLA genotype or CTLA-4 polymorphism on cytokine response in healthy children. 53 62
18782261 2008
21
Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. 53 62
18511417 2008
22
Molecular basis for tetanus toxin coreceptor interactions. 53 62
18543947 2008
23
Peanut-specific B and T cell responses are correlated in peanut-allergic but not in non-allergic individuals. 53 62
18564333 2008
24
Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. 53 62
18422727 2008
25
A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action. 53 62
18341617 2008
26
Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 production. 53 62
18450120 2008
27
Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. 53 62
18337418 2008
28
Lysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradation. 53 62
18292509 2008
29
Dynamics of intracellular oxygen in PC12 Cells upon stimulation of neurotransmission. 53 62
18086678 2008
30
Targeting the epithelial SNARE machinery by bacterial neurotoxins. 53 62
18369946 2008
31
An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. 53 62
17826026 2007
32
Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination. 53 62
17850592 2007
33
Effects of intravenous immunoglobulins on peripheral blood mononuclear cell activation in vitro. 53 62
17911484 2007
34
Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. 53 62
17654744 2007
35
What is the function of neuronal AP-3? 53 62
17567262 2007
36
Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. 53 62
17613604 2007
37
Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. 53 62
17544998 2007
38
v-SNARE cellubrevin is required for basolateral sorting of AP-1B-dependent cargo in polarized epithelial cells. 53 62
17485489 2007
39
Increased levels of fucosyltransferase IX and carbohydrate Lewis(x) adhesion determinant in human NT2N neurons. 53 62
17335083 2007
40
Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load. 53 62
17182676 2007
41
Parental smoking impairs vaccine responses in children with atopic genotypes. 53 62
17291854 2007
42
Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. 53 62
17691381 2007
43
Distinct functions of neuronal synaptobrevin in developing and mature fly photoreceptors. 53 62
16967508 2006
44
Effects of probiotic supplementation for the first 6 months of life on allergen- and vaccine-specific immune responses. 53 62
17014429 2006
45
Bacterial extract (OM-89) specific and non specific immunomodulation in rheumatoid arthritis patients. 53 62
16891218 2006
46
Increased apoptosis of CD20+ IgA + B cells is the basis for IgA deficiency: the molecular mechanism for correction in vitro by IL-10 and CD40L. 53 62
16758339 2006
47
Reduced tetanus antibody titers in overweight children. 53 62
16698670 2006
48
Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. 53 62
16404742 2006
49
Fifteen year experience of intrathecal baclofen treatment in Japan. 53 62
17370766 2006
50
Regulation of myeloid cell function through the CD200 receptor. 53 62
16365410 2006
Sources

Variations for Tetanus

About this section
Sources

Expression for Tetanus

About this section
Search GEO for disease gene expression data for Tetanus.
Sources

Pathways for Tetanus

About this section


Pathways directly related to Tetanus:

# Pathway Source
1 Neurotoxicity of clostridium toxins Reactome 66
2 Toxicity of tetanus toxin (tetX) Reactome 66

Pathways related to Tetanus according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.98 CD27 CD40LG CD79A IFNG IL10 IL13
2
ERK Signaling 64
Show member pathways
 13.85 LTA IL5 IL4 IL2RA IL2 IL13
3
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.67 LTA IL5 IL4 IL2RA IL2 IL13
4
TGF-Beta Pathway 64
Show member pathways
 13.54 LTA IL5 IL4 IL2RA IL2 IL13
5
Akt Signaling 64
Show member pathways
 13.46 LTA IL5 IL4 IL2RA IL2 IL13
6
PAK Pathway 64
Show member pathways
 13.34 LTA IL5 IL4 IL2RA IL2 IL13
7
Cytokine Signaling in Immune system 66
Show member pathways
 13.18 CD27 CD40LG IFNG IL10 IL13 IL2
8
Sertoli-Sertoli Cell Junction Dynamics 64
Show member pathways
 12.9 VAMP3 VAMP2 STX3 SNAP25 SNAP23
9
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.71 IFNG IL10 IL13 IL2 IL2RA IL4
10
NF-kappaB Signaling 3
12.64 IL4 IL2RA IL2 IL10 IFNG CD79A
11
wtCFTR and delta508-CFTR traffic / Generic schema (norm and CF) 22
Show member pathways
 12.5 VAMP7 VAMP2 SNAP25 SNAP23 NSF
12
NF-kappaB Pathway 70
Show member pathways
 12.43 IL5 IL2RA IL2 IL13
13
T-cell activation SARS-CoV-2 74
Show member pathways
 12.26 LTA IL5 IL4 IL2 IL10 IFNG
14
Sudden infant death syndrome (SIDS) susceptibility pathways 74
12.2 VAMP2 SNAP25 IL13 IL10
15
Neuroinflammation and glutamatergic signaling 74
12.18 LTA IL4 IL13 IL10 IFNG
16
IL2 signaling events mediated by STAT5 61
Show member pathways
 12.11 IFNG IL2 IL2RA IL4 LTA
17
MAPK Pathway 70
Show member pathways
 12.07 IL5 IL2RA IL2 IL13
18
IL12-mediated signaling events 61
Show member pathways
 12.03 IL4 IL2RA IL2 IFNG
19
Hematopoietic Stem Cells and Lineage-specific Markers 65
12.03 IL5 IL4 IL2RA IL2 IL10 IFNG
20
IL27-mediated signaling events 61
Show member pathways
 11.98 LTA IL2 IL10 IFNG
21
Interleukin-4 and Interleukin-13 signaling 66
11.93 IL4 IL13 IL10
22
Glucocorticoid receptor regulatory network 61
11.88 IL5 IL4 IL2 IL13 IFNG
23
Th17 Differentiation 65
Show member pathways
 11.85 IL4 IFNG CCR7
24
Acute viral myocarditis 74
11.85 IL2 IL10 IFNG CD40LG
25
Extrafollicular B cell activation by SARS-CoV-2 74
11.85 IL4 IL2 IL10 IFNG CD79A CD40LG
26
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 61
Show member pathways
 11.83 IL5 IL4 IL2RA IL2 IFNG CD40LG
27
Th17 cell differentiation pathway 74
11.8 IL4 IL2RA IL2 IFNG
28
AP-1 transcription factor network 61
11.8 IL5 IL4 IL2 IL10 IFNG
29
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 60
Show member pathways
 11.79 VAMP3 VAMP2 STX3 SNAP25
30
Inflammatory bowel disease signaling 74
Show member pathways
 11.76 IL5 IL4 IL2 IL13 IL10 IFNG
31
Dendritic Cells Developmental Lineage Pathway 65
11.75 IL2 IL10 IFNG
32
IL4-mediated signaling events 61
11.73 CD40LG IL10 IL4 IL5 LTA
33
Allograft rejection 74
11.73 CD40LG IFNG IL10 IL13 IL2 IL2RA
34
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.68 IL2 IFNG CD40LG
35
Lung fibrosis 74
11.68 IL5 IL4 IL13
36
IL 10 signaling pathway 67
11.67 LTA IL10 CD40LG
37
Synaptic vesicle pathway 74
11.65 VAMP2 STX3 SNAP25 NSF
38
THC Differentiation Pathway 64
11.63 IL4 IL2RA IL2 IL10 IFNG CD40LG
39
SHP2 signaling 61
11.6 IL2RA IL2 IFNG
40
Th2 Differentiation 65
11.53 IFNG IL10 IL13 IL2 IL2RA IL4
41
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
Show member pathways
 11.48 IL2RA IL2 IL10 IFNG
42
Inflammatory response pathway 74
11.47 IL5 IL4 IL2RA IL2 IFNG CD40LG
43
Delta508-CFTR traffic / Sorting endosome formation in CF 22
Show member pathways
 11.46 VAMP2 SNAP25 NSF
44
Innate Lymphoid Cells Differentiation 65
11.46 LTA IL5 IL4 IL2RA IL2 IL13
45
Development and heterogeneity of the ILC family 74
11.42 IL5 IL4 IL13 IFNG
46
Cytokines and inflammatory response 74
11.37 IFNG IL10 IL13 IL2 IL4 IL5
47
IL12 signaling mediated by STAT4 61
11.34 IL2RA IL2 IL13 IFNG
48
Immune infiltration in pancreatic cancer 74
11.31 IL5 IL4 IL2 IL13 IL10 IFNG
49
Other interleukin signaling 66
11.23 SNAP25 STX3 VAMP2
50
G-protein signaling_Rap2B regulation pathway 22
11.1 CD40LG IL10 IL13 IL2 IL4 IL5
Sources

GO Terms for Tetanus

About this section

Cellular components related to Tetanus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 10.1 IL2RA IL13 CD79A CD40LG CD27 CCR7
2 neuron projection GO:0043005 10.03 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
3 secretory granule GO:0030141 9.7 VAMP7 VAMP3 VAMP2 STX3
4 SNARE complex GO:0031201 9.4 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
5 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex GO:0070032 9.26 VAMP2 SNAP25

Biological processes related to Tetanus according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 vesicle-mediated transport GO:0016192 10.29 VAMP7 VAMP3 VAMP2 STX3 NSF
2 response to lipopolysaccharide GO:0032496 10.21 LTA IL13 IL10 CCR7
3 B cell differentiation GO:0030183 10.16 IL4 IL10 CD79A CD40LG
4 B cell proliferation GO:0042100 10.13 IL10 CD79A CD40LG
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.13 IFNG IL13 IL2 IL4
6 negative regulation of inflammatory response GO:0050728 10.13 IL4 IL2RA IL2 IL13 IL10
7 positive regulation of interleukin-12 production GO:0032735 10.12 IFNG CD40LG CCR7
8 positive regulation of interleukin-10 production GO:0032733 10.11 IL4 IL13 CD40LG
9 long-term synaptic potentiation GO:0060291 10.11 VAMP2 STX3 SNAP25 MPP2
10 negative regulation of endothelial cell apoptotic process GO:2000352 10.09 IL4 IL13 IL10
11 calcium-ion regulated exocytosis GO:0017156 10.09 VAMP7 VAMP3 VAMP2
12 Golgi to plasma membrane protein transport GO:0043001 10.08 VAMP3 VAMP2 NSF
13 immune response GO:0006955 10.06 CCR7 CD40LG IFNG IL10 IL13 IL2
14 microglial cell activation GO:0001774 10.04 IL4 IL13 IFNG
15 positive regulation of B cell proliferation GO:0030890 10.01 IL5 IL4 IL2 IL13
16 type 2 immune response GO:0042092 9.97 IL4 IL10
17 positive regulation of T cell proliferation GO:0042102 9.97 IL4 IL2RA IL2 CD40LG
18 neuroinflammatory response GO:0150076 9.96 IL4 IFNG
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.95 IL4 IL10 IFNG
20 regulation of isotype switching GO:0045191 9.93 IL10 IL4
21 synaptic vesicle fusion to presynaptic active zone membrane GO:0031629 9.93 SNAP23 SNAP25 STX3
22 exocytic insertion of neurotransmitter receptor to postsynaptic membrane GO:0098967 9.92 SNAP25 STX3
23 eosinophil degranulation GO:0043308 9.91 VAMP7 VAMP2
24 membrane fusion GO:0061025 9.91 VAMP3 VAMP2 STX3 SNAP23
25 positive regulation of immunoglobulin production GO:0002639 9.91 VAMP3 IL5 IL2 IL13 IL10
26 regulation of T cell homeostatic proliferation GO:0046013 9.89 IL2 IL2RA
27 positive regulation of plasma cell differentiation GO:1900100 9.88 IL10 IL2
28 negative regulation of complement-dependent cytotoxicity GO:1903660 9.88 IL13 IL4
29 positive regulation of T cell differentiation GO:0045582 9.87 CD27 IL2 IL2RA IL4
30 natural killer cell degranulation GO:0043320 9.85 VAMP7 VAMP2
31 regulation of CD4-positive, alpha-beta T cell proliferation GO:2000561 9.85 IL2RA IL2
32 neutrophil degranulation GO:0043312 9.83 VAMP2 VAMP7
33 negative regulation of lymphocyte proliferation GO:0050672 9.82 IL2 IL2RA
34 exocytosis GO:0006887 9.8 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
35 lymphocyte proliferation GO:0046651 9.67 IL2RA IL2
36 regulation of histamine secretion by mast cell GO:1903593 9.54 VAMP3 VAMP2
37 vesicle fusion GO:0006906 9.4 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23

Molecular functions related to Tetanus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SNARE binding GO:0000149 9.97 VAMP7 VAMP2 STX3 SNAP25 NSF
2 syntaxin-1 binding GO:0017075 9.86 VAMP3 VAMP2 SNAP25 NSF
3 cytokine activity GO:0005125 9.86 CD40LG IFNG IL10 IL13 IL2 IL4
4 syntaxin binding GO:0019905 9.81 VAMP3 VAMP2 SNAP25 SNAP23 NSF
5 SNAP receptor activity GO:0005484 9.4 VAMP7 VAMP3 VAMP2 STX3 SNAP25 SNAP23
Sources

Sources for Tetanus

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....